Bristol announces it will reaffirm its earnings guidance, and Glaxo acquires a 16% stake in South African firm Aspen Pharmacare.
AstraZeneca's blood-thinner outperforms Plavix in a late-stage trial, and Baxter's heparin is being investigated, according to a report.
AT&T is reportedly close to a $2.5 billion deal to buy pieces of Alltel Corp. from Verizon.
Widely held semiconductor stocks get a blistering, and Nvidia swings to a loss.
Google's CEO says he doesn't plan to resign from Apple's board despite a federal antitrust investigation.
GlaxoSmithKline is divesting its U.S. rights to Wellbutrin, sales of which have slipped 70%, as part of its strategy to reshape its U.S. business.
Genentech says the FDA has granted accelerated approval of its drug Avastin to treat a type of brain cancer.
Investors dunk Intel in the red, and Atmel gets downgraded amid disappointing quarterly sales.
Microsoft reportedly follows through on cuts announed in January.
Chip stocks are leading the tech sector higher, with Intel and AMD among the biggest winners.